Cisbio international, a developer of HTRF technology and services used in assay development and drug screening, announced the launch of HTRF Kinease TK at the SBS Conference in Montreal, Canada
HTRF Kinease TK is a universal and sensitive assay for high throughput screening of Tyrosine (Tyr) kinases, major targets in drug discovery, in particular in oncology research.
With the development of this new tool, Cisbio now offers its customers the ability to use a reliable and sensitive kinase screening platform based on one technology to address a broad range of kinase targets.
HTRF Kinease TK combines a peptide substrate called S4 and a single, proprietary monoclonal antibody with Cisbio's HTRF (homogeneous time resolved fluorescence) technology, a highly sensitive, robust technology for the detection of molecular interactions of proteins in vitro.
HTRF Kinease TK limits assay development time and is easily miniaturizable and flexible, meaning the assay can be performed under a wide range of kinase assay conditions, for instance with low consumption of enzyme or with any ATP concentration.
HTRF Kinease TK is the fifth kit in the HTRF Kinease platform, developed in collaboration with Millipore (Upstate) for profiling and HTS of Serine/Threonine (Ser/Thr) kinases.
Launched in March 2006, the platform consists of four kits combining three biotinylated substrates, S1, S2 and S3, with a monoclonal antibody and HTRF.
Since this new Tyr kinase assay is based on the same monoclonal antibody principle as HTRF Kinease, the implementation of the assay by Cisbio's existing HTRF Kinease customers is very straightforward.
"With the addition of HTRF Kinease TK to our kinase assay portfolio, Cisbio has now developed a rich kinase screening platform that has been validated on over 160 kinases," said Francois Degorce, head of HTRF marketing and business development at Cisbio international.
"Developing this monoclonal antibody-based kit to address Tyrosine kinases is testimony to our ongoing commitment to anticipate our customers' needs and provide them with easy-to-use, reliable, and sensitive assay development tools".
Cisbio complements its kinase screening platform with a comprehensive line of toolbox reagents and custom labelling and assay development services for the creation of highly specific Ser/Thr and Tyr kinase assays.
Cisbio enables its customers to use a single technology, HTRF, for both universal and specific kinase assays, saving valuable development time and cost.
